INCIDENCE OF NON-A, NON-B HEPATITIS AFTER SCREENING BLOOD-DONORS FOR ANTIBODIES TO HEPATITIS-C VIRUS AND SURROGATE MARKERS

JM BARRERA; M BRUGUERA; G ERCILLA; JM SANCHEZTAPIAS; M.P. GIL; C GIL; J COSTA; A GELABERT; J RODES; R CASTILLO

doi:10.7326/0003-4819-115-8-596

INCIDENCE OF NON-A, NON-B HEPATITIS AFTER SCREENING BLOOD-DONORS FOR ANTIBODIES TO HEPATITIS-C VIRUS AND SURROGATE MARKERS

JM BARRERA, M BRUGUERA, G ERCILLA, JM SANCHEZTAPIAS, M.P. GIL, C GIL, J COSTA, A GELABERT, J RODES, R CASTILLO

University of St Andrews

Research output: Contribution to journal › Article › peer-review

Abstract

Objective: To compare the effect of screening blood donors for antibodies to hepatitis C virus (anti-HCV) on the incidence of non-A, non-B hepatitis in recipients with that of screening blood donors for antibodies to hepatitis B core antigen (anti-HBc) and elevated alanine aminotransferase levels.

Design: Cohort analysis of serum samples from donors and recipients. Recipients were followed for 12 months to determine the occurrence of non-A, non-B hepatitis.

Setting: The blood-transmitted viruses unit and the liver unit of a university teaching hospital.

Subjects: A total of 250 patients who had open heart surgery and their 3142 blood donors.

Measurements: Donor sera were tested for anti-HCV by enzyme-linked immunosorbent assay (ELISA) and, in the event of a positive result, by recombinant immunoblot assay (RIBA). Antibodies to anti-HBc and serum alanine aminotransferase (ALT) levels were also measured. Measurements of anti-HCV and ALT activity in recipients were done before transfusion and at regular intervals during follow-up.

Main Results: Of the 250 transfusion recipients, 40 developed non-A, non-B hepatitis. Of the 3142 donors, 70 were positive for anti-HCV by ELISA, 440 were positive for anti-HBc, and 177 had alanine aminotransferase levels between 0.67 and 1.33-mu-kat/L. The sensitivity (87%), specificity (89%), positive predictive value (59%), and negative predictive value (97%) of blood-donor screening were higher for anti-HCV than for anti-HBc (82%, 36%, 21%, and 91%, respectively) and for elevated alanine aminotransferase levels (65%, 70%, 29%, and 91%, respectively). The expected number of donors excluded because of the presence of anti-HCV was considerably smaller than that of donors with positive results for surrogate markers of hepatitis.

Conclusions: Screening blood donors for the presence of anti-HCV is more accurate than screening for surrogate markers (anti-HBc and ALT) and protects more effectively against post-transfusion non-A, non-B hepatitis.

Original language	English
Pages (from-to)	596-600
Number of pages	5
Journal	Annals of Internal Medicine
Volume	115
Issue number	8
DOIs	https://doi.org/10.7326/0003-4819-115-8-596
Publication status	Published - 15 Oct 1991

Keywords

HEPATITIS, VIRAL, NON-A, NON-B
HEPATITIS-C VIRUS
HEPATITIS ANTIBODIES
BLOOD DONORS
BLOOD TRANSFUSION
TRANSFUSION-TRANSMITTED VIRUSES
CORE ANTIGEN
RECIPIENTS
EPIDEMIOLOGY
INFECTIVITY
AGENTS
ASSAY

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.7326/0003-4819-115-8-596

Cite this

@article{329d60548e464330b769d78560e4a606,

title = "INCIDENCE OF NON-A, NON-B HEPATITIS AFTER SCREENING BLOOD-DONORS FOR ANTIBODIES TO HEPATITIS-C VIRUS AND SURROGATE MARKERS",

abstract = "Objective: To compare the effect of screening blood donors for antibodies to hepatitis C virus (anti-HCV) on the incidence of non-A, non-B hepatitis in recipients with that of screening blood donors for antibodies to hepatitis B core antigen (anti-HBc) and elevated alanine aminotransferase levels.Design: Cohort analysis of serum samples from donors and recipients. Recipients were followed for 12 months to determine the occurrence of non-A, non-B hepatitis.Setting: The blood-transmitted viruses unit and the liver unit of a university teaching hospital.Subjects: A total of 250 patients who had open heart surgery and their 3142 blood donors.Measurements: Donor sera were tested for anti-HCV by enzyme-linked immunosorbent assay (ELISA) and, in the event of a positive result, by recombinant immunoblot assay (RIBA). Antibodies to anti-HBc and serum alanine aminotransferase (ALT) levels were also measured. Measurements of anti-HCV and ALT activity in recipients were done before transfusion and at regular intervals during follow-up.Main Results: Of the 250 transfusion recipients, 40 developed non-A, non-B hepatitis. Of the 3142 donors, 70 were positive for anti-HCV by ELISA, 440 were positive for anti-HBc, and 177 had alanine aminotransferase levels between 0.67 and 1.33-mu-kat/L. The sensitivity (87%), specificity (89%), positive predictive value (59%), and negative predictive value (97%) of blood-donor screening were higher for anti-HCV than for anti-HBc (82%, 36%, 21%, and 91%, respectively) and for elevated alanine aminotransferase levels (65%, 70%, 29%, and 91%, respectively). The expected number of donors excluded because of the presence of anti-HCV was considerably smaller than that of donors with positive results for surrogate markers of hepatitis.Conclusions: Screening blood donors for the presence of anti-HCV is more accurate than screening for surrogate markers (anti-HBc and ALT) and protects more effectively against post-transfusion non-A, non-B hepatitis.",

keywords = "HEPATITIS, VIRAL, NON-A, NON-B, HEPATITIS-C VIRUS, HEPATITIS ANTIBODIES, BLOOD DONORS, BLOOD TRANSFUSION, TRANSFUSION-TRANSMITTED VIRUSES, CORE ANTIGEN, RECIPIENTS, EPIDEMIOLOGY, INFECTIVITY, AGENTS, ASSAY",

author = "JM BARRERA and M BRUGUERA and G ERCILLA and JM SANCHEZTAPIAS and M.P. GIL and C GIL and J COSTA and A GELABERT and J RODES and R CASTILLO",

year = "1991",

month = oct,

day = "15",

doi = "10.7326/0003-4819-115-8-596",

language = "English",

volume = "115",

pages = "596--600",

journal = "Annals of Internal Medicine",

issn = "0003-4819",

publisher = "American College of Physicians",

number = "8",

}

TY - JOUR

T1 - INCIDENCE OF NON-A, NON-B HEPATITIS AFTER SCREENING BLOOD-DONORS FOR ANTIBODIES TO HEPATITIS-C VIRUS AND SURROGATE MARKERS

AU - BARRERA, JM

AU - BRUGUERA, M

AU - ERCILLA, G

AU - SANCHEZTAPIAS, JM

AU - GIL, M.P.

AU - GIL, C

AU - COSTA, J

AU - GELABERT, A

AU - RODES, J

AU - CASTILLO, R

PY - 1991/10/15

Y1 - 1991/10/15

N2 - Objective: To compare the effect of screening blood donors for antibodies to hepatitis C virus (anti-HCV) on the incidence of non-A, non-B hepatitis in recipients with that of screening blood donors for antibodies to hepatitis B core antigen (anti-HBc) and elevated alanine aminotransferase levels.Design: Cohort analysis of serum samples from donors and recipients. Recipients were followed for 12 months to determine the occurrence of non-A, non-B hepatitis.Setting: The blood-transmitted viruses unit and the liver unit of a university teaching hospital.Subjects: A total of 250 patients who had open heart surgery and their 3142 blood donors.Measurements: Donor sera were tested for anti-HCV by enzyme-linked immunosorbent assay (ELISA) and, in the event of a positive result, by recombinant immunoblot assay (RIBA). Antibodies to anti-HBc and serum alanine aminotransferase (ALT) levels were also measured. Measurements of anti-HCV and ALT activity in recipients were done before transfusion and at regular intervals during follow-up.Main Results: Of the 250 transfusion recipients, 40 developed non-A, non-B hepatitis. Of the 3142 donors, 70 were positive for anti-HCV by ELISA, 440 were positive for anti-HBc, and 177 had alanine aminotransferase levels between 0.67 and 1.33-mu-kat/L. The sensitivity (87%), specificity (89%), positive predictive value (59%), and negative predictive value (97%) of blood-donor screening were higher for anti-HCV than for anti-HBc (82%, 36%, 21%, and 91%, respectively) and for elevated alanine aminotransferase levels (65%, 70%, 29%, and 91%, respectively). The expected number of donors excluded because of the presence of anti-HCV was considerably smaller than that of donors with positive results for surrogate markers of hepatitis.Conclusions: Screening blood donors for the presence of anti-HCV is more accurate than screening for surrogate markers (anti-HBc and ALT) and protects more effectively against post-transfusion non-A, non-B hepatitis.

AB - Objective: To compare the effect of screening blood donors for antibodies to hepatitis C virus (anti-HCV) on the incidence of non-A, non-B hepatitis in recipients with that of screening blood donors for antibodies to hepatitis B core antigen (anti-HBc) and elevated alanine aminotransferase levels.Design: Cohort analysis of serum samples from donors and recipients. Recipients were followed for 12 months to determine the occurrence of non-A, non-B hepatitis.Setting: The blood-transmitted viruses unit and the liver unit of a university teaching hospital.Subjects: A total of 250 patients who had open heart surgery and their 3142 blood donors.Measurements: Donor sera were tested for anti-HCV by enzyme-linked immunosorbent assay (ELISA) and, in the event of a positive result, by recombinant immunoblot assay (RIBA). Antibodies to anti-HBc and serum alanine aminotransferase (ALT) levels were also measured. Measurements of anti-HCV and ALT activity in recipients were done before transfusion and at regular intervals during follow-up.Main Results: Of the 250 transfusion recipients, 40 developed non-A, non-B hepatitis. Of the 3142 donors, 70 were positive for anti-HCV by ELISA, 440 were positive for anti-HBc, and 177 had alanine aminotransferase levels between 0.67 and 1.33-mu-kat/L. The sensitivity (87%), specificity (89%), positive predictive value (59%), and negative predictive value (97%) of blood-donor screening were higher for anti-HCV than for anti-HBc (82%, 36%, 21%, and 91%, respectively) and for elevated alanine aminotransferase levels (65%, 70%, 29%, and 91%, respectively). The expected number of donors excluded because of the presence of anti-HCV was considerably smaller than that of donors with positive results for surrogate markers of hepatitis.Conclusions: Screening blood donors for the presence of anti-HCV is more accurate than screening for surrogate markers (anti-HBc and ALT) and protects more effectively against post-transfusion non-A, non-B hepatitis.

KW - HEPATITIS, VIRAL, NON-A, NON-B

KW - HEPATITIS-C VIRUS

KW - HEPATITIS ANTIBODIES

KW - BLOOD DONORS

KW - BLOOD TRANSFUSION

KW - TRANSFUSION-TRANSMITTED VIRUSES

KW - CORE ANTIGEN

KW - RECIPIENTS

KW - EPIDEMIOLOGY

KW - INFECTIVITY

KW - AGENTS

KW - ASSAY

U2 - 10.7326/0003-4819-115-8-596

DO - 10.7326/0003-4819-115-8-596

M3 - Article

SN - 0003-4819

VL - 115

SP - 596

EP - 600

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

IS - 8

ER -

INCIDENCE OF NON-A, NON-B HEPATITIS AFTER SCREENING BLOOD-DONORS FOR ANTIBODIES TO HEPATITIS-C VIRUS AND SURROGATE MARKERS

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this